Wave reports third-quarter results while Wave Life Sciences stock trades at EUR 3.08

Published on 10/27/2026 at 14:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue rose to USD 13.2 million from USD 7.6 million. Wave Life Sciences stock trades at EUR 3.08 on October 27, 2026.

Liquidity and clinical milestones

Wave reported USD 13.2 million in third-quarter 2026 revenue and a USD 61.9 million net loss on October 27, 2026.
Cash, cash equivalents and marketable securities totaled USD 431.0 million on September 30, 2026, supporting operations into the third quarter of 2028.
Wave Life Sciences stock traded at EUR 3.08 at 2:00 p.m. CEST at Lang & Schwarz on October 27, 2026.

WVE, US94352A1043, Illustration mit AI erstellt.

Wave Life Sciences (ISIN US94352A1043) was trading at EUR 3.08 at Lang & Schwarz on October 27, 2026 at 2:00 p.m. CEST. The biotechnology company reported third-quarter 2026 results and pipeline updates, according to GlobeNewswire.

Third-quarter figures sharpen picture

Wave recognized USD 13.2 million in revenue for the third quarter of 2026, up from USD 7.6 million in the third quarter of 2025. Net loss reached USD 61.9 million, compared with USD 53.9 million in the prior-year quarter, while research and development expenses rose to USD 53.8 million from USD 45.9 million.

The figures show a company still funding a costly clinical pipeline while collaboration revenue provides support. Wave's third-quarter diluted loss was USD 0.30 per share, compared with USD 0.32 in the third quarter of 2025.

Cash runway supports pipeline work

Cash, cash equivalents and marketable securities totaled USD 431.0 million as of September 30, 2026. Wave also expects a USD 12.0 million milestone from GSK in the fourth quarter of 2026 and said its resources should fund operations into the third quarter of 2028, according to GlobeNewswire.

The main clinical focus remains WVE-006 for alpha-1 antitrypsin deficiency and WVE-007 for obesity. Wave said a clinical trial application for WVE-008 in PNPLA3 liver disease remains on track for the fourth quarter of 2026.

What comes next for Wave?

The next dated company event is Wave's virtual Research Day on November 4, 2026 at 9:30 a.m. ET, listed on the company's investor events page. The program is scheduled to cover the RNA medicines platform and PNPLA3 liver disease.

Analyst interest remains a counterweight to the losses. UBS initiated coverage with a Buy rating and a USD 11.00 price target on October 15, 2026, according to MarketScreener.

Trading context for investors

Wave's results combine higher quarterly revenue with a wider net loss and a cash position designed to support several clinical programs. The November 4, 2026 Research Day and fourth-quarter development milestones are the next company-specific dates for the stock.

Wave Life Sciences was trading at EUR 3.08 at Lang & Schwarz on October 27, 2026 at 2:00 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Wave Life Sciences stock.